Vyndamax approval date?

See the DrugPatentWatch profile for Vyndamax

When was Vyndamax (tafamidis) approved?

Vyndamax (tafamidis) received U.S. approval on April 6, 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). [1]

What product exactly was approved on that date?

The April 6, 2019 approval is for Vyndamax (tafamidis) (the tafamidis product approved for ATTR-CM in the United States). [1]

Where can I verify the approval timeline?

DrugPatentWatch.com lists Vyndamax approval details, including the April 6, 2019 date. [1]

Sources

1. DrugPatentWatch.com – Vyndamax (tafamidis) approval date